Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

We recently compiled a list of the 13 Cheap High Dividend Stocks To Invest In Now. In this article, we are going to take a ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Merck & Co., Inc.

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.  Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare ...

Now that Merck stock has been beaten down, it offers a higher yield than we usually see from the well-established ...

Merck’s new drugs – Winrevair and Capvaxive – have been gaining momentum. On the flip side, Gardasil sales fell 17% to $1.55 billion, due to a continued decline in China. Januvia and Janumet ...

Merck reported adjusted EPS of $1.72 ... Across the commercial portfolio, the analyst remains bullish on Winrevair's potential. Analyst Shibutani writes that the company is well-equipped to ...